Immutep Ltd · ASX:IMM
Immutep — Australia Biotech Invest & Partnering 2018
11 slides from Immutep's conference presentation, Oct 30, 2018
Slide 1: The global leader in developing LAG-3 therapeutics
For personal use only The global leader in developing LAG-3 therapeutics Australia Biotech Invest & Partnering 30th October 2018 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further
Slide 3: Company Snapshot
Company Snapshot For personal use only Capital Structure • Globally active biotechnology company with IMM (Australian Securities Exchange) Ticker symbols IMMP (NASDAQ) operations in Australia, Europe and U.S. 3.08 billion ordinary shares Securities on issue(1) 8.83 million American Depository (as at
Slide 4: LAG-3 Overview & Product Candidates
For personal use only LAG-3 Overview & Product Candidates 4
Slide 5: LAG-3 as a Therapeutic Target
LAG-3 as a Therapeutic Target For personal use only LAG-3 is widely expressed on tumour infiltrating lymphocytes (TILs) and cytotoxic T cells → Prime target for an immune checkpoint blocker → Positive LAG-3/ MHC Class II Interaction regulation of antigen presenting cells (APC) → increase in antigen
Slide 6: Targeting LAG-3 May Lead to Multiple Therapeutics in Numerous Indications
Targeting LAG-3 May Lead to Multiple Therapeutics in Numerous Indications For personal use only IMMUNOSTIMULATION IMMUNOSUPPRESSION IMP321 APC Activator APC Agonistic mAb IMP761 MHCII Depleting LAG-3 mAb Antagonistic Partnered with mAb Partnered with LAG-3 IMP701 T-Cell T-Cell IMP731 Rheumatoid IBD
Slide 7: Oncology and Autoimmune Pipeline
Oncology and Autoimmune Pipeline* For personal use only Program Preclinical Phase I Phase II Late Stage Commercial Rights/Partners AIPAC 2019 (Chemo-IO Combo) Eftilagimod Alpha TACTI-002 (1) 2019/2020 § Global (LAG-3lg or IMP321), (IO-IO Combo) Rights APC activating (2),(3),(5) INSIGHT-004 fusion pr
Slide 8: Efti (IMP321) in Melanoma
Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Single Case at 1 mg efti For personal use only Efficacy: Metastatic Melanoma pre-pembro week 9 (pembro) week 25 (combo) week 37 (combo) R L R L R L R L Tumour progression week 49 (Pembro mono) week 64 (PFS-FU) R L R L All lesions disappeared → C
Slide 9: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview For personal use only Immutep is the leader in developing LAG-3 modulating therapeutics Program Eftilagimod Alpha (IMP321) LAG525 (IMP701) GSK2831781 (IMP731) Relatlimab Company BMS Late stage 1 trial 1 trial 2 trials Phase 2 1 trial 4 trials 6 trials Phase 1 2 t
Slide 10: Outlook: Potential News Flow and Milestones
Outlook For personal use only Potential News Flow and Milestones TACTI-mel data from fourth patient cohort (30 mg dose at cycle 1): H2 2018 Clinical TACTI-002 to commence, Phase II trial in collaboration with MSD: H2 2018 TACTI-002 first data in 2019 IMP761 preclinical data: 2018/ 2019 INSIGHT singl
Slide 11: Thank you!
11 For personal use only Thank you!